BRAF and neoplasm: In addition to BRAF, the second most common mutation in MAPK pathway is the small GTPase NRAS (25%), and the third is the tumour suppressor and the negative regulator of RAS, neurofibromin 1 (NF1) (14%); both these mutations lead to the activation of the MAPK pathway and increased ERK signalling.14